SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is currently a focal point for investors debating its status as a deeply undervalued fintech leader versus a long-term value trap, as the community intensely scrutinizes the company's aggressive share buyback strategy and potential for AI-driven margin expansion. While significant buyout rumors and strategic partnerships continue to drive speculative interest, sentiment remains sharply divided between those accumulating shares at historic lows and frustrated shareholders demanding more decisive leadership to overcome sustained price stagnation.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is experiencing heightened volatility and trading momentum driven by a strong quarterly earnings report that exceeded expectations and a growing community narrative linking the company to the upcoming SpaceX IPO. Investors are actively debating the company's path to profitability and potential for a short squeeze, while long-term supporters emphasize its critical role as a manufacturing supplier for aerospace and defense leaders.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is capturing significant investor attention as the community debates its long-term potential in the MS market, focusing on the successful commercial launch of Briumvi and the strategic implications of upcoming subcutaneous dosing data. Discussions center on whether the company's growth trajectory and pipeline expansion make it a prime candidate for a high-premium buyout, or if management will continue building the business independently.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

iShares Silver Trust (SLV) is currently experiencing high volatility as investors grapple with complex macroeconomic factors, including shifting inflation data and ongoing geopolitical uncertainties. The community remains deeply divided, with many traders debating whether the current price action represents a temporary correction or a long-term accumulation opportunity for silver’s critical role in AI and industrial sectors.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWM is seeing active community debate as investors weigh strong economic data and the potential for a small-cap breakout against the risk of persistent interest rate pressure. Traders are focused on volatility ahead of upcoming macroeconomic updates, with many actively hedging against a potential correction while others look for signs of a market rotation into smaller-cap names.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is trending as investors grapple with significant volatility and a breakdown below its 200-day moving average, fueling intense debate over whether current price action represents a classic buying opportunity or the start of a deeper structural correction. Community discourse remains sharply divided, with bulls highlighting long-term hedging against record federal debt and central bank accumulation, while bears emphasize technical weakness and potential downside risk driven by cooling geopolitical tensions and shifting interest rate expectations.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing significant downward pressure as investors grapple with broad market volatility and concerns over AI-related capital expenditure debt. Despite analyst optimism and bullish sentiment regarding the company's cloud infrastructure backlog, the community remains divided between those panic-selling and others aggressively buying the dip ahead of upcoming earnings.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The SPY is experiencing significant intraday volatility driven by geopolitical tensions in the Strait of Hormuz and anticipation surrounding upcoming inflation data. The market community is actively debating whether the recent price swings indicate a sustained downturn or if coordinated interventions and algorithmic activity are creating a 'buy the dip' trap for retail traders.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is experiencing intense intraday volatility as investors react to escalating geopolitical tensions in the Middle East and uncertainty surrounding the upcoming CPI data. Community discussion is heavily divided between bears pointing to a potential bubble unwind in AI-linked tech and bulls aggressively trading the frequent, large-scale V-shaped recovery patterns.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

American Airlines is seeing increased volatility as investors weigh stronger-than-expected revenue against a lowered full-year earnings outlook driven by escalating fuel costs. The market is also closely monitoring the company's expansion of in-flight connectivity through SpaceX's Starlink, while social media sentiment remains divided over the long-term impact of regional instability on travel demand.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Capricor Therapeutics Q1 2026 Earnings Call Transcript

Capricor Therapeutics Says NS Pharma Delays Could Threaten Access To Duchenne Therapy

Capricor sued Nippon Shinyaku over Deramiocel distribution terms, citing pricing issues and patient access risks.read more...

Nasdaq, S&P 500 Futures Rise Ahead Of Jobs Report As Iran Ceasefire Holds: Why NVDA, IREN, CRWV, RKLB, UPWK, CAPR Are In Focus

Equity

Data from Stocktwits shows that retail traders’ sentiment has remained ‘bullish’ on SPY and QQQ this week.


CAPR Stock Sinks After-Hours: Capricor Launches Legal Fight Over DMD Therapy Rollout Ahead Of FDA Review

Capricor is seeking court approval to pursue an alternative commercialization path for Deramiocel and wants parts of the agreement terminated.

Capricor Therapeutics (CAPR) Projected to Post Earnings on Tuesday

Capricor Therapeutics (NASDAQ:CAPR) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 12. (View Earnings Report at...

Oppenheimer & Co. Inc. Cuts Stock Holdings in Capricor Therapeutics, Inc. $CAPR

Oppenheimer & Co. Inc. trimmed its position in shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) by 40.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 80,813 shares of the biotechnology company's stock after selling 54,600 s...

Capricor Therapeutics (NASDAQ:CAPR) Shares Up 7.1% - Still a Buy?

Capricor Therapeutics (NASDAQ:CAPR) Trading 7.1% Higher - What's Next...

CAPR Stock In Focus: Ex-Exec Eyed For FDA Role Says Drug Approvals Are Not ‘Best-In-Class’ Signals

Former Capricor executive Houman David Hemmati said FDA approval should be viewed as a “building permit,” not proof a drug is the best option.

Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.5%  - What's Next?

Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.5% - Should You Sell...

Moody Aldrich Partners LLC Takes Position in Capricor Therapeutics, Inc. $CAPR

Moody Aldrich Partners LLC purchased a new stake in Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 208,755 shares of the biotechnology compan...

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Bullish Sentiment

Investors are closely monitoring the upcoming August 22nd FDA decision for Deramiocel, viewing it as the primary catalyst for valuation.

Ongoing tension and litigation involving Nippon Shinyaku regarding distribution rights dominate board sentiment and impact short-term price volatility.

Many stockholders are holding firm and accumulating shares, anticipating that the high short interest will fuel a sharp upward move upon positive news.

Investors characterize recent price dips as a golden entry point for long-term holders confident in the drug's fundamental clinical science.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.59	--	--	N/A
Q1 '26	-$0.51	-$0.59	-16.26%	MISSED
Q4 '25	-$0.51	-$0.62	-21.81%	MISSED
Q3 '25	-$0.55	-$0.54	1.22%	BEAT
Q2 '25	-$0.48	-$0.57	-19.75%	MISSED

CAPRCapricor Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Latest CAPR News